Impressive 12-Month Patient Outcomes from SONATA Pivotal IDE Trial Being Highlighted Redwood City, CA – Nov 12, 2018 - Gynesonics, a women’s healthcare company focused on the development of advanced minimally invasive solutions for the treatment of uterine conditions, today announced that its
Gynesonics Receives FDA Clearance to Market Sonata® System
Advanced technology offers potential to become a new standard of care for fibroid treatment Redwood City, CA – August 22, 2018 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, today announced that it has received
Gynesonics Announces Results from Pivotal IDE Trial for Incision Free Treatment of Uterine Fibroids
Results highlight robust Sonata System design and its potential to become a standard of care for fibroid treatment Redwood City, CA – January 9, 2018 - Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today
Gynesonics Announces Submission of FDA 510K for Incision-Free Treatment of Symptomatic Uterine Fibroids
Novel uterus-preserving Sonata System is first incision-free treatment to address majority of fibroids transcervically Redwood City, CA – December 21, 2017 - Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for uterine fibroids, today announced its
Gynesonics names James Sparks Vice President of Manufacturing
Respected Leader in Medical Device Manufacturing and Engineering Management Redwood City, CA – March 30, 2017 - Gynesonics, a women’s healthcare company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of symptomatic
Data from Sonata Technology Platform Featured in Presentations at AAGL Global Congress in Orlando
First Health Economic Outcomes Research with Sonata Treatment to be Presented Redwood City, CA – Nov 10, 2016 - Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions, today announced that its Sonata® System
Sonata Technology Platform Featured in Presentations at Upcoming Congress of the German Society of Obstetrics and Gynecology (DGGG)
Increasing Body of Evidence Further Demonstrates Compelling Outcomes Redwood City, CA – October 19, 2016 - Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions, today announced that its Sonata® System
Gynesonics Announces Early Completion of Enrollment in the SONATA FDA Clinical Trial for Incision Free Treatment of Symptomatic Uterine Fibroids
Company Expects to Submit Trial Results to FDA in Fourth Quarter of 2017 Redwood City, CA – October 18, 2016 - Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for treatment of benign uterine conditions, today announced the completion of